Black men twice as likely to die from prostate cancer compared to white men
the ONA take:
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men, according to an English population study published in BMC Medicine.
Additionally, Asian men are half as likely to be diagnosed, or die from, prostate cancer in their lifetime compared to white men.
Researchers led by Alison Cooper of Prostate Cancer UK and Public Health England studied prostate cancer incidence and mortality data in England from 2008 to 2010 from a variety of sources, including Public Health England and the Office for National Statistics. In total, their sample size included 25,635,649 men, with 102,252 prostate cancer diagnoses and 26,521 deaths as a result of prostate cancer.
They found that lifetime risk of being diagnosed with prostate cancer in England was about 1 in 8 (13.3 percent) for white men, 1 in 4 (29.3 percent) for black men, and 1 in 13 (7.9 percent) for Asian men.
Risk of dying from prostate cancer in England was found to be about 1 in 24 (4.2 percent) in white men, 1 in 12 (8.7 percent) in black men, and 1 in 44 (2.3 percent) in Asian men.
Independent of ethnicity, white, black and Asian men with prostate cancer diagnosis were found to have a one third chance of dying from the disease.
Further work is needed to understand the mechanisms for the higher risk found in black men.
Black men are twice as likely to be diagnosed with, or die from, prostate cancer in their lifetime compared to white men.
Sign Up for Free e-newsletters
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Breast Cancer Deaths Decrease Sharply Since 2000
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|